Hiroaki Kanemura

Sakai, 5900197, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.

Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma.

Journal: Med (New York, N.Y.)

Published: February 21, 2026

Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.

Efficacy and safety of first-line lenvatinib in patients with advanced or recurrent thymic carcinoma in the real-world setting.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 31, 2025

Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).

Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 27, 2025

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.

Journal: Cancer research communications

Published: August 24, 2025

Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.

Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.

Journal: BMC pulmonary medicine

Published: August 11, 2025

Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study).

Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study).

Journal: Cancer treatment and research communications

Published: July 29, 2025

Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.

Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 03, 2025

Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings.

Lenvatinib for patients with previously treated advanced thymic carcinoma in real-world settings.

Journal: ESMO open

Published: December 28, 2024

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.

Journal: Thoracic cancer

Published: September 24, 2024

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.

Journal: JTO clinical and research reports

Published: December 28, 2023

The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.

The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study.

Journal: Frontiers in immunology

Published: October 21, 2023

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report.

Journal: JTO clinical and research reports

Published: January 25, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026